Skip to main content

Perrigo Company(PRGO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low30.69
Day High31.55
Open:30.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Perrigo Announces Leadership Update
PR Newswire
Perrigo to Attend Upcoming Consumer Investor Conferences
PR Newswire
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
PR Newswire
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
PR Newswire
Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference
Motley Fool
With a Big Catalyst in Hand, Is Perrigo Company a Buy?
Motley Fool
FDA Approves Over-the-Counter Birth Control Pill. Is the Pill Maker's Stock Set to Soar?
PR Newswire
Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive
PR Newswire
Perrigo Appoints Patrick Lockwood-Taylor as President and CEO
PR Newswire
Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference
PR Newswire
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE
PR Newswire
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
PR Newswire
Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
PR Newswire
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
PR Newswire
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
PR Newswire
Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023
Barchart
Stocks Set To Open Mixed As Investors Await Powell Testimony
PR Newswire
Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference
PR Newswire
Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day
PR Newswire
Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
PR Newswire
Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023
The Globe and Mail
Perrigo: Top 25 Undervalued Dow Jones Composite Index Stocks (PRGO)
Motley Fool
Why Perrigo Stock Tanked on Tuesday
PR Newswire
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
Newswire.ca
Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula
PR Newswire
Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022
The Globe and Mail
Perrigo: Top 25 Undervalued Dow Jones Composite Index Stocks (PRGO)
PR Newswire
PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE
MarketBeat
Is Sanofi A Buy, Despite Recent Stumbles?
PR Newswire
PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY
PR Newswire
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS
PR Newswire
PERRIGO ANNOUNCES QUARTERLY DIVIDEND

Profile

Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International'(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.